Evotec stock starts EUR 2 million buyback for employee program
Published on 11/11/2026 at 17:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec adds a share repurchase plan
- The program is intended to support obligations under an employee share plan.
- Purchases are planned exclusively through Xetra and may run until December 18, 2026.
- Repurchased shares are intended to be converted into American Depositary Shares.
Evotec SE has launched a share repurchase program to meet obligations under an employee share plan, adding a new capital-market measure after its third-quarter update. The management board approved the program on November 9, 2026, according to the Finanzen.net report carrying the EQS announcement.
Buyback targets employee-plan obligations
Evotec intends to acquire up to 365,000 shares between November 10 and December 18, 2026. The purchases are to be executed exclusively through electronic trading on Xetra, with an independent credit institution deciding the timing of individual transactions.
The repurchased shares will subsequently be converted into American Depositary Shares. Evotec said these ADS will be used exclusively for obligations under an employee share program and issued only to current or former employees of the company or an affiliated entity.
Program adds a new capital-market lever
The announcement gives investors a defined use for the repurchased stock rather than signaling a change to the company's operating outlook. Evotec may terminate, suspend or resume the program in line with applicable legal requirements, while transactions must be disclosed no later than the end of the seventh trading day after execution.
Evotec stock traded at 3.16 euros on Lang & Schwarz at 17:10 CET on Wednesday, November 11, 2026.
Evotec SE stock facts
- Company: Evotec SE
- ISIN: DE0005664809
- Lang & Schwarz quote: 3.16 euros at 17:10 CET on November 11, 2026
- Repurchase volume: Up to 365,000 shares
- Maximum purchase price: EUR 2 million, excluding incidental acquisition costs
- Purchase venue: Xetra
European biotechnology shares remain sensitive to financing conditions, clinical progress and partnership announcements; investors can follow the broader DAX market environment.
